Loading...
XSHE
300289
Market cap564mUSD
Dec 05, Last price  
7.34CNY
1D
1.24%
1Q
-9.49%
Jan 2017
-41.04%
IPO
17.63%
Name

Beijing Leadman Biochemistry Co Ltd

Chart & Performance

D1W1MN
XSHE:300289 chart
P/E
P/S
10.79
EPS
Div Yield, %
0.14%
Shrs. gr., 5y
5.13%
Rev. gr., 5y
-6.39%
Revenues
370m
-19.79%
103,809,747143,265,563185,624,994252,083,942317,273,827343,630,223536,970,837681,675,798533,391,826575,978,026654,804,224515,143,483471,510,962564,057,983705,976,839461,554,624370,226,869
Net income
-75m
L
26,162,27841,414,91154,398,70271,850,81998,287,089110,072,010128,281,332157,219,57169,648,57173,067,13540,471,7246,309,184022,419,197015,337,378-75,101,335
CFO
62m
-53.57%
21,982,23831,262,53453,464,38829,344,91857,855,64190,446,0140177,817,69181,775,815120,965,20681,020,993124,648,403135,559,303119,058,284108,933,825134,420,51562,406,242
Dividend
May 17, 20240.01 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Beijing Leadman Biochemistry Co.,Ltd. engages in the research and development, manufacture, and sale of in vitro diagnostic products in the People's Republic of China. The company offers biochemical raw materials, such as enzymes, coenzymes, antibodies, buffers, enzyme substrates, culture media, stain reagents, amino acids, and other products primarily for biotechnology, clinical diagnosis, drug development, chemical production, and other related applications. It also provides biochemistry diagnostic and companion reagents. In addition, the company offers medical instruments, such as EnigmaML, an automated molecular test platform for use in clinical laboratory and at the point-of-care, including clinics, doctor's surgeries, and pharmacies; DiaSys InnovaStar, an automatic compact POCT analyzer to deliver result quality comparable to measurements on laboratory analyzers; DiaSys Respons, a random access bench top analyzer; CI1000 automatic chemiluminescence immunoassay analyzers; and IDS-isys, an instrument to enhance performance and productivity. The company was founded in 1997 and is headquartered in Beijing, the People's Republic of China.
IPO date
Feb 16, 2012
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT